OSI Shareholders File Class Action Suits Over Tarceva Data
This article was originally published in The Pink Sheet Daily
Executive Summary
OSI shareholders have filed several class-action lawsuits alleging the company made misleading claims about Tarceva prior to approval
You may also be interested in...
Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit
Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.
Tarceva Average Treatment Duration Is Approximately Four Months, OSI Says
Market opportunity for Tarceva should be evaluated based on mean duration of therapy, which is “a little over four months,” rather than median progression free survival of roughly nine weeks, company says. OSI attempts to correct investor “confusion” about commercial opportunity for the Genentech/OSI lung cancer agent.
Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin
Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.